Experienced in Diffuse Midline Glioma H3 K27M-Mutant

Dr. Mary R. Welch

Neurology
Trustees Of Columbia University In The City Of New York
51 W 51st St, Fl 3 Suite 360, 
New York, NY 
Offers Telehealth
Experienced in Diffuse Midline Glioma H3 K27M-Mutant
Trustees Of Columbia University In The City Of New York
51 W 51st St, Fl 3 Suite 360, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mary Welch is a Neurologist in New York, New York. Dr. Welch is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. Her top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Her clinical research consists of co-authoring 21 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northwell Health
  • INSURANCE PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
51 W 51st St, Fl 3 Suite 360, New York, NY 10019
Other Locations
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
710 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Other, Drug, Radiation
Study Phase: Phase 1
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
A Phase II Trial of Osimertinib (AZD9291) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Bevacizumab, Osimertinib
Study Phase: Phase 2
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Bevacizumab, Cediranib, Cediranib Maleate, Olaparib
Study Phase: Phase 2
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Telaglenastat Hydrochloride, Temozolomide
Study Phase: Phase 1
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint Blockade
An Open-Label, Phase II Multicenter Study of Rituximab or Tocilizumab for Steroid-Dependent Immune-Related Adverse Events Due to Immune Checkpoint Blockade
Enrollment Status: Active_not_recruiting
Publish Date: May 12, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating Agents
Enrollment Status: Active_not_recruiting
Publish Date: July 18, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
View 7 Less Clinical Trials

21 Total Publications

Management of Complications in Neuro-oncology Patients.
Management of Complications in Neuro-oncology Patients.
Journal: Continuum (Minneapolis, Minn.)
Published: December 12, 2023
Similar Doctors
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Craig P. Nolan
Neurology
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Craig P. Nolan
Neurology

Mskcc Regional Network

650 Commack Rd, 
Commack, NY 
 (36.1 miles away)
631-623-4034
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Craig Nolan is a Neurologist in Commack, New York. Dr. Nolan is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Glioma, Posterior Fossa Tumor, Primitive Neuroectodermal Tumor (PNET), and Metastatic Brain Tumor.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Andrew Lin
Neurology
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Andrew Lin
Neurology

Memorial Neurology Group

1275 York Ave, 
New York, NY 
 (1.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Lin is a Neurologist in New York, New York. Dr. Lin is rated as a Distinguished provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Brain Tumor, Glioma, Astrocytoma, and Glioblastoma.

Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Nagesh B. Krish
Neurology | Sleep Medicine
Advanced in Diffuse Midline Glioma H3 K27M-Mutant
Dr. Nagesh B. Krish
Neurology | Sleep Medicine
176 Palisade Ave, 
Jersey City, NJ 
 (4.1 miles away)
201-795-8200
Experience:
43+ years
Languages Spoken:
English, Spanish, Tamil, Telugu
See accepted insurances
Accepting New Patients

Nagesh Krish is a Neurologist and a Sleep Medicine provider in Jersey City, New Jersey. Dr. Krish has been practicing medicine for over 43 years and is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His top areas of expertise are Chronic Inflammatory Demyelinating Polyneuropathy, Dravet Syndrome, Memory Loss, and Seizures. Dr. Krish is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Welch's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 8 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile